One To Watch

Legend Biotech

A Somerset, New Jersey-based cell therapy biotechnology company that generated $597 million in Carvykti net trade sales in Q1 2026 and sent shares up 42% in June 2026 on striking Phase I in vivo CAR-T lymphoma data.

Company Overview

Legend Biotech's June 2026 disclosure of early in vivo CAR-T data — a 100% objective response rate in relapsed B-cell lymphoma without lymphodepleting chemotherapy — crystallized the argument that the company is more than a single-product Carvykti story. The Somerset, NJ-based biotechnology company develops cell therapies across autologous and allogeneic CAR-T, TCR-T, and NK cell platforms, with oncology as the organizing thesis. It trades on Nasdaq under LEGN and carries a market capitalization of approximately $6.7 billion as of early June 2026. Carvykti, its co-commercialized BCMA-directed CAR-T for multiple myeloma, is already one of the field's fastest-growing approved cell therapies.

Headquarters and Global Presence

Legend Biotech is headquartered in Somerset, New Jersey, and retains manufacturing and research infrastructure with links to Nanjing, China, reflecting its GenScript parentage. The company operates commercially across the United States and Europe, where Carvykti is approved by the EMA.

Founding and History

Founded in 2014 as a subsidiary of GenScript Biotech, Legend Biotech originated in Nanjing before expanding its operational center to New Jersey. The transformative deal came in December 2017, when Janssen Biotech paid $350 million upfront for an exclusive worldwide license to co-develop and co-commercialize cilta-cel — a partnership that capitalized the company through to commercialization. Legend listed on Nasdaq on June 5, 2020, pricing 18,425,000 ADS at $23.00 each and raising approximately $423.8 million in gross proceeds. Carvykti received its first FDA approval in February 2022, completing the journey from startup to commercial-stage biotech in under a decade.

Therapy Areas and Focus

Legend's pipeline is concentrated in hematologic malignancies, with multiple myeloma the commercial anchor and B-cell lymphomas now the frontier for its next-generation platform. The in vivo CAR-T program LB2501 targets relapsed/refractory B-cell non-Hodgkin lymphoma, a setting where single-target CAR-T therapies routinely fail through antigen-loss escape. The DLL3-targeting asset LB2102 extends the ambition into solid tumors, specifically small-cell lung cancer — a notoriously treatment-resistant indication where cell therapy has historically made little headway. The breadth reflects a deliberate attempt to build a durable cell therapy franchise beyond the myeloma market.

Technology Platforms and Modalities

The company's approved product, Carvykti, uses a conventional autologous CAR-T model: patient cells are extracted, engineered to express two BCMA-targeting domains, and reinfused after lymphodepletion. Its next-generation candidate LB2501 breaks that mold entirely, using Legend's proprietary TaVec lentiviral vector platform to engineer CAR-T cells directly inside the patient following a single off-the-shelf intravenous infusion — no apheresis, no lymphodepleting chemotherapy, no manufacturing delay. Dual CD19/CD20 targeting is built into LB2501's design specifically to counter the antigen-loss escape that undermines current single-target CD19 therapies. If the platform holds up at scale, it addresses the two largest structural criticisms of autologous CAR-T: logistical complexity and single-antigen vulnerability.

Key Pipeline and Programs

Carvykti (ciltacabtagene autoleucel) is a BCMA-directed autologous CAR-T approved by the FDA in February 2022 for relapsed/refractory multiple myeloma and expanded in April 2024 to second-line use — the first and only BCMA-targeted CAR-T cleared at that earlier treatment line. It is co-commercialized with Janssen Biotech and generated $597 million in net trade sales in Q1 2026 alone, representing 62% year-over-year growth.

LB2501 is an investigational in vivo CAR-T built on the TaVec lentiviral vector platform, targeting CD19 and CD20 simultaneously in relapsed/refractory B-cell non-Hodgkin lymphoma. Phase I first-in-human data disclosed June 2, 2026, showed a 100% ORR (6/6) and 83.3% complete response rate (5/6) at dose level 2, with all responses ongoing as of the April 1, 2026 cutoff. No dose-limiting toxicities, no serious adverse events, no deaths, and no ICANS were observed across 12 treated patients. Full data will be presented at the EHA 2026 Congress in Stockholm, June 11-14, 2026.

LB2102 is a DLL3-targeting CAR-T candidate for small-cell lung cancer and other DLL3-expressing solid tumors, out-licensed to Novartis in November 2023 for $100 million upfront and up to approximately $1.01 billion in milestones. Novartis is advancing it using its T-Charge manufacturing platform. Legend also terminated its Phase I trial of LB1901, an autologous CAR-T for T-cell lymphoma, in June 2024.

Recent Developments

The defining event of mid-2026 is the LB2501 Phase I disclosure on June 2, which drove a 42% single-day share price gain — a magnitude of market reaction that signals how the field weights a credible in vivo CAR-T proof-of-concept. Q1 2026 financials, reported May 12, showed Carvykti net trade sales of $597 million and a narrowed net loss of $54.3 million, versus a $101.0 million loss a year earlier; the adjusted net loss was just $10.5 million. Legend ended the quarter with approximately $835 million in cash and no long-term debt. The company refreshed its leadership team in 2025, with Ying Huang, PhD, assuming the CEO role and Carlos Santos joining as CFO in August 2025.

Key Personnel

Ying Huang, PhD, serves as Chief Executive Officer, having assumed the role in 2025; she brings scientific and operational leadership shaped by Legend's expansion from a GenScript subsidiary to a commercial-stage biotech. Frank (Fangliang) Fan, PhD, is Chief Scientific Officer and co-founder, having led the scientific vision since 2014, including the foundational BCMA CAR-T work that became Carvykti. Carlos Santos was appointed Chief Financial Officer effective August 18, 2025, taking responsibility for financial strategy as Carvykti revenue scales toward profitability.

Strategic Partnerships

The Janssen Biotech collaboration, struck in December 2017 for $350 million upfront, remains Legend's most consequential relationship — structuring co-development, co-commercialization, and milestone payments for Carvykti globally. The November 2023 license to Novartis for DLL3-targeting CAR-T therapies, including LB2102, brought $100 million upfront and up to $1.01 billion in milestones, while offloading solid-tumor development costs onto a larger partner with manufacturing infrastructure. Together, the two deals demonstrate a partnership model that funds internal R&D without dilutive equity raises.

FAQ Section

LB2501 delivers a lentiviral vector encoding the CAR construct directly into the patient via a single intravenous infusion, generating functional CAR-T cells in vivo without apheresis or lymphodepleting chemotherapy. This collapses the weeks-long autologous manufacturing cycle to a single off-the-shelf vial and removes the lymphodepletion toxicity burden entirely. The dual CD19/CD20 targeting simultaneously addresses the antigen-loss escape mechanism that causes many patients to relapse after current single-target therapies.

B-cell maturation antigen (BCMA) is expressed at high levels on malignant plasma cells and at low levels on normal tissue, making it a relatively clean tumor target in myeloma. Carvykti's CAR construct incorporates two BCMA-binding domains — a design intended to improve avidity and cell killing compared with single-domain constructs. The April 2024 label expansion to second-line use, where patient performance status is generally better and disease burden lower, materially enlarged the addressable population and is the primary driver of Carvykti's 62% year-over-year sales growth in Q1 2026.

Among approved CAR-T therapies, Carvykti is the only BCMA-directed product cleared for second-line myeloma use, a regulatory distinction its closest competitor, Bristol Myers Squibb's Abecma (ide-cel), has not achieved. LB2501 goes further still — if its Phase I signal holds, it would be the first clinically validated in vivo CAR-T platform, removing the apheresis and lymphodepletion requirements that currently limit CAR-T to specialist centers. The DLL3 program via Novartis adds a solid-tumor vector that most pure-play CAR-T companies have struggled to build credibly.

The 100% ORR and 83.3% complete response rate at dose level 2 in six evaluable patients is genuinely striking for a first-in-human cohort, and the absence of ICANS, dose-limiting toxicities, and serious adverse events is clinically meaningful given lymphodepleting chemotherapy was withheld. The caveat is the scale: 12 patients total across two dose levels is an early, uncontrolled signal in a single tumor type, and durability data are immature. The EHA 2026 oral presentation in Stockholm will offer a more detailed breakdown of patient characteristics and response kinetics, which is the next meaningful evidence checkpoint.

Hematologic malignancies dominate — multiple myeloma through Carvykti and B-cell non-Hodgkin lymphoma through LB2501. The DLL3 program via Novartis extends the reach into solid tumors, specifically small-cell lung cancer. Legend quietly closed its T-cell lymphoma program (LB1901) in June 2024, a decision that sharpened focus toward the two areas where the clinical evidence base is stronger and commercial precedents clearer.

Carvykti is firmly in commercial scale-up: $597 million in Q1 2026 net trade sales and a narrowed adjusted net loss of $10.5 million signal the company is approaching operational profitability on the back of a single product. The $835 million cash position with no long-term debt provides meaningful runway to advance LB2501 through dose-escalation and into a larger expansion cohort. LB2501 Phase I dose escalation is ongoing, with the next clinical milestone likely being a recommended Phase II dose and early efficacy expansion data in the second half of 2026 or early 2027.

The key watchpoints, both upside and downside, cluster around platform validation and commercial execution:

LB2501 durability and dose escalation: the 100% ORR in 12 patients is an early, uncontrolled signal — a recommended Phase II dose and durable responses in H2 2026 or early 2027 are needed to confirm the in vivo CAR-T thesis.
EHA 2026 readout (June 11-14, Stockholm): fuller patient-level data and response kinetics for LB2501 are the next concrete evidence checkpoint.
Carvykti commercial trajectory: sustaining 62% year-on-year growth ($597 million in Q1 2026) and defending the second-line label against Bristol Myers Squibb’s Abecma is the core commercial test.
Path to profitability: with an adjusted net loss of $10.5 million, ~$835 million in cash and no debt, watch whether Carvykti scale tips the company into operating profit.
Novartis DLL3 program (LB2102): milestone progress in small-cell lung cancer would validate Legend’s reach into solid tumors beyond hematology.

Want to Update your Company's Profile?